Literature DB >> 23417781

The future of inpatient anticoagulation management.

Allison E Burnett1, Toby C Trujillo.   

Abstract

Anticoagulation therapy management has evolved dramatically in both the outpatient and inpatient arenas over the last 30 years in the interest of optimizing patient safety and outcomes. With the advent of target specific oral anticoagulants and next generation antiplatelet agents, a new world of "antithrombosis management" is quickly becoming evident. Additionally, significant changes to the healthcare system in the United States are anticipated with the implementation of the Healthcare Affordability Act. Collectively, these changes constitute the next major evolution in the management of patients on antithrombotic therapy. This article is intended to serve as a call to action for inpatient anticoagulation management services and specialists to familiarize themselves with potential changes, consider the impact they may have and proactively optimize their structure and services to be better able to embrace and capitalize on change.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23417781     DOI: 10.1007/s11239-013-0892-1

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  59 in total

1.  Effectiveness of a pharmacist-acquired medication history in promoting patient safety.

Authors:  Tina M Nester; LaDonna S Hale
Journal:  Am J Health Syst Pharm       Date:  2002-11-15       Impact factor: 2.637

Review 2.  Determination of dabigatran in human plasma samples.

Authors:  Job Harenberg; Christina Giese; Svetlana Marx; Roland Krämer
Journal:  Semin Thromb Hemost       Date:  2012-02-07       Impact factor: 4.180

Review 3.  Hospital-based medication reconciliation practices: a systematic review.

Authors:  Stephanie K Mueller; Kelly Cunningham Sponsler; Sunil Kripalani; Jeffrey L Schnipper
Journal:  Arch Intern Med       Date:  2012-07-23

4.  The impact of follow-up telephone calls to patients after hospitalization.

Authors:  V Dudas; T Bookwalter; K M Kerr; S Z Pantilat
Journal:  Am J Med       Date:  2001-12-21       Impact factor: 4.965

Review 5.  Assays for measuring rivaroxaban: their suitability and limitations.

Authors:  Edelgard Lindhoff-Last; Meyer Michel Samama; Thomas L Ortel; Jeffrey I Weitz; Theodore E Spiro
Journal:  Ther Drug Monit       Date:  2010-12       Impact factor: 3.681

6.  Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy.

Authors:  G Palareti; N Leali; S Coccheri; M Poggi; C Manotti; A D'Angelo; V Pengo; N Erba; M Moia; N Ciavarella; G Devoto; M Berrettini; S Musolesi
Journal:  Lancet       Date:  1996-08-17       Impact factor: 79.321

7.  Risk factors for intracranial hemorrhage in outpatients taking warfarin.

Authors:  E M Hylek; D E Singer
Journal:  Ann Intern Med       Date:  1994-06-01       Impact factor: 25.391

8.  Continuity of care and patient outcomes after hospital discharge.

Authors:  Carl van Walraven; Muhammad Mamdani; Jiming Fang; Peter C Austin
Journal:  J Gen Intern Med       Date:  2004-06       Impact factor: 5.128

9.  Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States.

Authors:  William L Baker; Deborah A Cios; Stephen D Sander; Craig I Coleman
Journal:  J Manag Care Pharm       Date:  2009-04

10.  Pharmacist- versus physician-obtained medication histories.

Authors:  Todd A Reeder; Alan Mutnick
Journal:  Am J Health Syst Pharm       Date:  2008-05-01       Impact factor: 2.637

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.